Skip to main content
ConductScienceScienceDex

Glenn Short Iii

NIH Rank #1310
Unclaimed recordClaim profile
  • Top 10% Funded
  • Early Career

Researcher identity and coverage

Current affiliation
Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
NIH RePORTER identity
Profile ID 79944137Search this ID in NIH RePORTER
ScienceDex PI coverage
FY2025 through FY2026Career claims are limited to the years shown.

NIH Funding · FY2026

Linked Award Amount
$2.7M
Full award amounts, FY2026
Award Records
1
Records listing this PI
Award-Linked Rank
#1,310
By linked amount among FY2026 PIs
Earliest Year Loaded
2025
ScienceDex PI coverage

One scientist record

NIH portfolios and SHARE

This is the common ScienceDex page for Glenn Short Iii. NIH portfolio memberships are contextual views of this scientist, while SHARE Score, S-Index, and S-Impact describe the researcher's global sharing track record.

Review metric definitions

FY2026 NIH portfolio memberships

No institute-level portfolio release is available for this scientist and fiscal year yet. Existing award history remains unchanged above.

Researcher-associated datasets

These datasets are linked to this researcher's ShareScore identity. This does not by itself prove that an NIH portfolio funded each dataset.

No compatible author-to-dataset release is published. Dataset records are unavailable, not zero.

Award-linked funding history

Linked NIH award amounts and rank by fiscal year.

FY2026 award records by amount

NIH award records listing Glenn Short Iii as a PI. Multi-PI records show the full award amount for context.

  • 5UG3DA064403-02UG3
    Optimization and Development of Non-Hallucinogenic 5-HT2A/2C Agonists as Opioid Use Disorder Therapeutics
    Atai Therapeutics, Inc.
    $2.7M
    award amount

Award organization

Organizations that administered FY2026 awards listing Glenn Short Iii as a PI.

FY2026 award administered by Atai Therapeutics, Inc. (NY).

Coverage and award-record milestones

Computed from the fiscal years currently available in ScienceDex.

  1. 2025
    First NIH Award
    Atai Therapeutics, Inc.
  2. 2025
    $500K Cumulative Funding
  3. 2025
    $1M Cumulative Funding
  4. 2025
    $2M Cumulative Funding
  5. 2025
    Entered Top 50% Nationally
    Ranked #3562
  6. 2025
    Entered Top 25% Nationally
    Ranked #3562
  7. 2026
    $5M Cumulative Funding
  8. 2026
    Entered Top 10% Nationally
    Ranked #1310

Explore further

Find collaborators for Glenn Short Iii

Search NIH-funded principal investigators by topic, department, or activity.

Open Find Collaborators →

Benchmark grant budgets

Compare median NIH grant budgets across departments, mechanisms, and years.

Open Grant Budget Benchmark →